Pembrolizumab
Pharmaceutical drug used in cancer treatment
📊 Rating
2 news mentions · 👍 0 likes · 👎 0 dislikes
📌 Topics
- Pharmaceuticals (2)
- Finance (2)
- Corporate Earnings (1)
- Economy (1)
🏷️ Keywords
Merck (2) · Keytruda (2) · Wall Street (2) · Revenue (1) · Earnings Report (1) · Pharmaceutical Industry (1) · Biotechnology (1) · Patent expiration (1) · Sales forecast (1) · Biosimilars (1) · Pharma news (1)
📖 Key Information
Pembrolizumab, sold under the brand name Keytruda, is a humanized monoclonal antibody, more specifically a PD-1 inhibitor, used in cancer immunotherapy to treat many types of cancer. It is administered by slow intravenous injection.
Common side effects include fatigue, musculoskeletal pain, decreased appetite, itchy skin, diarrhea, nausea, rash, fever, cough, difficulty breathing, constipation, pain, and abdominal pain.
📰 Related News (2)
🔗 Entity Intersection Graph
People and organizations frequently mentioned alongside Pembrolizumab:
- 🌐 Merck (2 shared articles)
- 🌐 Pharmaceutical industry (1 shared articles)
- 🌐 Revenue (1 shared articles)
- 🌐 Term of patent (1 shared articles)
- 🌐 Biosimilar (1 shared articles)